Literature DB >> 16014670

Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles.

S P Linn-Rasker1, A H M van der Helm-van Mil, F A van Gaalen, M Kloppenburg, R R P de Vries, S le Cessie, F C Breedveld, R E M Toes, T W J Huizinga.   

Abstract

OBJECTIVES: To study the gene-environment interaction of tobacco exposure and shared epitope on autoantibodies in patients with rheumatoid arthritis and undifferentiated arthritis.
METHODS: From incident cases of arthritis (n = 1305), patients who did not fulfil any classification criteria (undifferentiated arthritis (n = 486)) and those who fulfilled the American College of Rheumatology criteria for rheumatoid arthritis (n = 407) were identified. IgM rheumatoid factor (RF), anti-cyclic-citrullinated peptide (CCP) antibodies, and HLA-DRB1 alleles were determined.
RESULTS: In rheumatoid arthritis, an interaction was found between tobacco exposure and shared epitope for the presence of anti-CCP antibodies, as the odds ratio for anti-CCP antibodies in patients having both tobacco exposure (TE) and shared epitope (SE) was higher than the summed odds ratios of patients having only tobacco exposure or shared epitope (odds ratios: TE+/SE-, 1.07; TE-/SE+, 2.49; and TE+/SE+, 5.27-all relative to TE-/SE-). A similar effect was found for RF, but stratification showed that the interaction primarily associated with the anti-CCP antibody response. In patients with undifferentiated arthritis at two weeks, or with persistent undifferentiated arthritis after one year, no interaction between tobacco exposure and shared epitope was observed for the presence of autoantibodies.
CONCLUSIONS: Tobacco exposure increases the risk factor for anti-CCP antibodies only in shared epitope positive patients with rheumatoid arthritis. The gene-environment interaction between smoking and shared epitope leading to autoantibodies is specific for rheumatoid arthritis and is not observed in undifferentiated arthritis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014670      PMCID: PMC1798061          DOI: 10.1136/ard.2005.041079

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

1.  Nodular disease in rheumatoid arthritis: association with cigarette smoking and HLA-DRB1/TNF gene interaction.

Authors:  Derek L Mattey; Peter T Dawes; June Fisher; Ann Brownfield; Wendy Thomson; Ali H Hajeer; William E R Ollier
Journal:  J Rheumatol       Date:  2002-11       Impact factor: 4.666

Review 2.  Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome.

Authors:  Deborah P M Symmons
Journal:  Best Pract Res Clin Rheumatol       Date:  2002-12       Impact factor: 4.098

3.  Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins.

Authors:  Tom W J Huizinga; Christopher I Amos; Annette H M van der Helm-van Mil; Wei Chen; Floris A van Gaalen; Damini Jawaheer; Geziena M T Schreuder; Mark Wener; Ferdinand C Breedveld; Naila Ahmad; Raymond F Lum; Rene R P de Vries; Peter K Gregersen; Rene E M Toes; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2005-11

Review 4.  Genetics of rheumatoid arthritis: is there a scientific explanation for the human leukocyte antigen association?

Authors:  Jane H Buckner; Gerald T Nepom
Journal:  Curr Opin Rheumatol       Date:  2002-05       Impact factor: 5.006

5.  The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis.

Authors:  B J Harrison; A J Silman; N J Wiles; D G Scott; D P Symmons
Journal:  Arthritis Rheum       Date:  2001-02

6.  Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis.

Authors:  S Bas; S Genevay; O Meyer; C Gabay
Journal:  Rheumatology (Oxford)       Date:  2003-05       Impact factor: 7.580

7.  Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage.

Authors:  L R Lard; M Boers; A Verhoeven; K Vos; H Visser; J M W Hazes; A H Zwinderman; G M T Schreuder; F C Breedveld; R R P De Vries; S van der Linden; E Zanelli; T W J Huizinga
Journal:  Arthritis Rheum       Date:  2002-04

8.  Age at diagnosis of smoking-related disease.

Authors:  Jiajian Chen
Journal:  Health Rep       Date:  2003-02       Impact factor: 4.796

9.  Consistent low prevalence of arthritis in quebec: findings from a provincial variation study in Canada based on several canadian population health surveys.

Authors:  Peizhong P Wang; Elizabeth M Badley
Journal:  J Rheumatol       Date:  2003-01       Impact factor: 4.666

Review 10.  Epidemiology and genetics of rheumatoid arthritis.

Authors:  Alan J Silman; Jacqueline E Pearson
Journal:  Arthritis Res       Date:  2002-05-09
View more
  98 in total

1.  Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.

Authors:  Jing Shi; Rachel Knevel; Parawee Suwannalai; Michael P van der Linden; George M C Janssen; Peter A van Veelen; Nivine E W Levarht; Annette H M van der Helm-van Mil; Anthony Cerami; Tom W J Huizinga; Rene E M Toes; Leendert A Trouw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

2.  C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis.

Authors:  Munitta Muthana; Sarah Hawtree; Adam Wilshaw; Eimear Linehan; Hannah Roberts; Sachin Khetan; Gbadebo Adeleke; Fiona Wright; Mohammed Akil; Ursula Fearon; Douglas Veale; Barbara Ciani; Anthony G Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-27       Impact factor: 11.205

3.  Epidemiology: Interpreting studies of interactions between RA risk factors.

Authors:  Elizabeth W Karlson; Karen H Costenbader
Journal:  Nat Rev Rheumatol       Date:  2010-02       Impact factor: 20.543

4.  Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease.

Authors:  Chase S Correia; Melissa R Briones; Rong Guo; Rochella A Ostrowski
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

Review 5.  Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis.

Authors:  William P Arend; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

6.  The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases.

Authors:  Ct Chou; Ht Liao; Ch Chen; Ws Chen; Hp Wang; Ky Su
Journal:  Biomark Insights       Date:  2007-05-03

Review 7.  Rheumatoid arthritis and smoking: putting the pieces together.

Authors:  Zsuzsanna Baka; Edit Buzás; György Nagy
Journal:  Arthritis Res Ther       Date:  2009-08-03       Impact factor: 5.156

8.  Mutual information for testing gene-environment interaction.

Authors:  Xuesen Wu; Li Jin; Momiao Xiong
Journal:  PLoS One       Date:  2009-02-24       Impact factor: 3.240

Review 9.  Developments in the scientific understanding of rheumatoid arthritis.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

Review 10.  Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies.

Authors:  Y W Song; E H Kang
Journal:  QJM       Date:  2009-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.